Strong combination CD38 antibody/protease inhibitor combination therapy is FDA approved.

Multiple myeloma is a type of blood cancer characterized by multiple remissions and recurrences of the disease, and the outcome of the patient deteriorates each time it relapses.
with the spread of immunomodulation drugs (IMiDs) after disease progression, resistance to these drugs may increase and the number of patients who continue to progress after treatment may increase over time.
, patients need a non-lMiD treatment plan to treat a recurrence of the disease.
Kyprolis is a protease inhibitor that induces the death of multiple myeloma cells by inhibiting the function of proteases, leading to the accumulation of abnormal proteins in cells.
Darzalex is Janssen's single-clone antibody targeting CD38, which induces cell death by combining it with highly expressed CD38 on the surface of multiple myeloma cells.
these two drugs are important representatives of protease inhibitors and CD38 antibody drugs respectively, both of which have been approved for the treatment of multiple myeloma.
approval is based on a Phase 1b clinical trial called EQUULEUS and a Phase 3 clinical trial called CANDOR.
CANDOR is the first randomized Phase 3 clinical trial to compare DKd with Kyprolis and Desemisson (Kd) combinations in R/R MM patients.
the study reached its primary endpoint, the risk of disease progression or death in patients treated with DKd decreased by 37% (HR-0.63; 95% CI:0.464, 0.854; p-0.0014) compared to Kd treatment.
.